Care Management Solutions Market Analysis, Trends and Demand,

Care Management Solutions Market

The growth of global care management solutions market is led by growing geriatric population, increasing demand for quality of care and increasing government initiatives to promote patient-centric care, increasing prevalence of chronic diseases, advancing IT and big data capabilities and growing medical tourism. Initiatives to move the burden of threat from healthcare payers to providers and need to reduce healthcare cost are further expected to boost the demand of these solutions. The fastest increase in demand of care management solutions during the forecast period is expected to be witnessed in chronic care management segment, due to increasing demand of improving quality of care and save time for providers. Based on component, software segment leads the global market in terms of size, due to technological advancement in IT solution, growth of cloud computing and increased access of internet across the globe.

Explore Report at: https://www.psmarketresearch.com/market-analysis/care-management-solutions-market

Increasing prevalence of chronic diseases is driving the growth of the global care management solutions market due to increasing demand for quality of care. The prevalence of chronic diseases, such as heart disease, cancer, stroke and respiratory disease, are increasing due to the alteration in lifestyle and lack of access to preventive care. According to the Centers for Disease Control and Prevention (CDC), approximately 117 million people in the U.S. had one or more chronic health conditions in 2012.

Care management solution is an integrated healthcare solution that offers products and services to improve quality of care of patients. It identifies the need of care, manage care, monitor results and outcomes, assess patient’s needs, and establish the appropriate care plan to support their needs. It combines analytics, data integration, and coordination of care capabilities into a single solution.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/care-management-solutions-market/report-sample

The key players operating in the global market are Allscripts Healthcare solutions Inc., Cerner Corporation, Epic Corporation, Inc., Wellentive Inc., I2I System Inc, and IBM Corporation.

Cardiovascular Information System Market Insight, Analysis and Forecast to 2023

Cardiovascular Information System Market

The global cardiovascular information system market is witnessing significant growth due to increasing prevalence of cardiovascular diseases, growing government initiates towards electronic health record system implementation and growing rate of medication errors. The remote access to data and images, and reduced IT burden in the diagnostic center and hospitals are supporting the demand of CVIS. Moreover, better interoperability and increasing healthcare cost are further expected to boost the market. Based on mode of operation, web-based segment leads the global market in terms of size, owing to high rate of awareness, improved interoperability, reduced IT burden in hospitals and relatively less cost. Based on component, the market for service segment is expected to grow at the fastest rate during the forecast period, due to upgradation of services for the complex software introduction and requirement for extensive training.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cardiovascular-information-system-market

The increasing demand for cloud based solutions is expected to create opportunities for the players in the market. The unexplored market in developing economies is also creating abundant opportunities for the cardiovascular information system market to grow at a significant rate in the coming years. However, high cost of cardiovascular information, lack of standard healthcare protocol towards implementation of CVIS solution in developing countries and reluctance of healthcare provides to implement cardiovascular information system are the key factors hampering the growth of the global market.

Geographically, North America has been the largest market for cardiovascular information system, owing to increasing incidence of cardiovascular disease, well established healthcare infrastructure, and strict privacy and security regulation in the region. The U.S. contributed largest revenue to the North American as well as global cardiovascular information system market. The increase in integration of the electronic health record maintenance system and favorable government policies are driving the growth of the U.S. cardiovascular information system. Globally, the cardiovascular information system market is expected to witness the fastest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to large pool of patient, improving healthcare infrastructure, increasing incidence of cardiovascular disease, and growing medical tourism in the region.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cardiovascular-information-system-market/report-sample

The key players operating in the global cardiovascular information system market are Philips Healthcare, McKesson Corporation, Philips Healthcare, General Electric Company, Siemens AG, AGFA Healthcare and Cerner Corporation.

Revenue Cycle Management Market Analysis, Forecast to 2023

Revenue Cycle Management Market

The worldwide revenue cycle management market is witnessing considerable growth due to increasing regulatory requirements for the usage of revenue cycle management, increase in recovery audits due to changing healthcare regulations and increasing government support for revenue cycle management. Moreover, process improvements in healthcare organizations, increasing prevalence of chronic diseases and growing geriatric population are resulting in increased demand of revenue cycle management. Increasing number of patients and growth in demand for health insurance, increasing healthcare delivery cost, and decline in reimbursement rates are further supporting the market growth. Based on product type, the market for integrated segment is estimated to increase at the faster rate during the forecast period, due to increasing demand of integrated solution to achieve process efficiency and cost reduction. Based on deployment method, the market for web-based segment leads the global market due to growing demand for mobile support system for better patient engagement solution.

Explore Report at: https://www.psmarketresearch.com/market-analysis/revenue-cycle-management-market

The increasing demand for cloud based revenue cycle solution and vendor consolidation to provide end-to-end solution are expected to create opportunities for the players in the market. In addition, immense unexplored market in developing economies are creating abundant opportunities for the revenue cycle management market to grow at a significant rate in the coming years. However, high cost of deployment, lack of data security, limited trained IT personnel, and infrastructural loop holes in developing countries are the key factors hampering the growth of the global market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/revenue-cycle-management-market/report-sample

The key players operating in the global market are Cerner Corporation, McKesson Corporation, Athenahealth Inc., Eclinicalworks LLC., Quest Diagnostics Incorporated, Allscripts Healthcare Solutions Inc., GE Healthcare, and Epic Systems Corporation.

Hepcidin antagonist, Pipeline Analysis, 2017

The hepcidin antagonist pipeline has more than 10 drugs. In pipeline analysis, drugs are analyzed on the basis of route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.

Explore Report at: https://www.psmarketresearch.com/market-analysis/hepcidin-antagonist-pipeline-analysis

Phase III

Phase III clinical trial known for the comparison of new treatments with the standard treatment in which the safety, efficacy and side effects of new intervention is compared with the already existing treatment. The Phase III clinical trial takes around 2-3 years to complete and the total number of participants vary from 100-1,000. In Hepcidin antagonist, there are 3 drugs in phase III clinical trial. For instance, Luspatercept, a phase III drug candidate of Celgene Corporation is being developed in collaboration with Acceleron Pharma, Inc., for the treatment of anemia with myelodysplastic syndromes and anemia associated with beta thalassaemia.

Phase II

NOX-H94 is a phase II drug candidate of NOXXON Pharma N.V. The drug candidate is an anti-hepcidin single-stranded structured L-RNA oligonucleotide conjugated to 40kDa polyethylene glycol. Phase II clinical trial is the second phase that answer safety, efficacy and dosing of the new intervention. It takes around 2 years to complete and between 100 – 120 patients participate in the Phase II trial.

Phase I

PRS 080, a phase I/II drug candidate is under development by Pieris Pharmaceuticals, Inc. for the treatment of anemia. The drug candidate is an hepcidin antagonist, which can restore iron utilization and erythropoiesis.  The company mentioned that the compound has successfully shown a favorable safety profile in healthy volunteers and is expected to complete a multi-dose trial by mid of 2017. In Phase I clinical trial, safety of the new intervention is determined. The trial takes around 1-2 years to complete and the total number of volunteers participating in the trial vary between 15 – 30.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/hepcidin-antagonist-pipeline-analysis/report-sample

Pre-Clinical

Pipeline analysis provides description about the key companies developing hepcidin antagonist drugs. Some of the key players actively involved in the research and development are Celgene Corporation, Akebia Therapeutics, Inc., FibroGen, Inc., Noxxon Pharma AG and Tolero Pharmaceuticals, Inc.

Janus Kinase Inhibitors Pipeline Analysis – Designation, Collaboration and Developments

Janus kinase (JAK) inhibitors block Janus kinase activator enzymes and interrupt signaling pathway. It plays an important role in host defense, oncology, autoimmunity and hematological cancers, which makes them an important target for therapeutics. Many signal transduction pathways are done by JAK activity for the normal signaling. The abnormal aberration in JAKs activity can lead to diseased state. For instance, over activation of JAK can lead to tumorigenesis whereas loss of JAK can lead to severe combined immunodeficiency. Janus Kinases family contains JAK 1, JAK 2, JAK 3 and a group of cytoplasmic non-receptor Tyrosine kinases (NRTKs).

Explore Report at: https://www.psmarketresearch.com/market-analysis/janus-kinase-inhibitors-pipeline-analysis

The cytokine receptor is associated with JAKs present on the surface of cells. JAK tyrosine kinase family are primarily associated with signal transduction originating from extracellular ligands, which often interact with transmembrane receptors. Different JAK tyrosine kinase are the key components in mediating signaling process such as expression of genes involved in proliferation, apoptosis, migration, and differentiation. They play a major role in immune defense as many signaling events involved in both innate and adaptive immunity is mediated by JAKs. They are also involved in cell growth, survival, development, and differentiation of immune cells. Mutation in JAKs leads to the immunodeficiency disorders.

Aclaris Therapeutics, Inc. is developing ATI-50001, a pre-clinical drug candidate for the treatment of alopecia universalis and alopecia totalis. Pre-clinical study is also known as animal study. It is done before testing a drug in people to find out the toxicity profile of the drug. Pre-Clinical study is of two types, including In vitro and In vivo.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/janus-kinase-inhibitors-pipeline-analysis/report-sample

Pipeline analysis provides description about the key companies developing JAK inhibitor drugs. Some of the key players actively involved in the research and development are Galapagos NV, AbbVie Inc., Eli Lilly and Company, Gilead Sciences, Inc., Astellas Pharma Inc., CTI BioPharma Corp., Portola Pharmaceuticals, Inc., Japan Tobacco International, Incyte Corporation, Pfizer, Inc., and Asana BioSciences, LLC.

Hodgkin’s Lymphoma Therapeutics Pipeline Analysis 2017

Hodgkin_s Lymphoma Therapeutics Pipeline

The Hodgkin’s lymphoma therapeutics pipeline is expected to witness considerable growth in the coming years as the researchers are making novel drug delivery system for the treatment for cancer. The government agencies such as National Cancer Institute and American Cancer Society are supporting the growth of the Hodgkin’s lymphoma (HL) therapeutics pipeline by providing funding, designations and grants for speeding up the drug development process. High prevalence of cancer, increasing awareness regarding cancer treatment, technological advancements and high demand for safe and effective medication are driving the growth of the Hodgkin’s Lymphoma therapeutics pipeline.

Explore Report at: https://www.psmarketresearch.com/market-analysis/hodgkins-lymphoma-therapeutics-pipeline-analysis

Hodgkin lymphoma (HL) or Hodgkin’s disease is an uncommon cancer of the lymphatic system, such as lymph nodes. The lymphatic system is made up of a network of vessels and glands that spread throughout the body. The vessels of lymphatic system known as lymphocytes carrying clear fluid known as lymph, contains lymphocytes (white blood cells that help combat infection). The lymphatic is a part of the human body’s immune system. In Hodgkin’s lymphoma, the patient experiences a painless swelling in a lymph node, usually in the neck, armpit or groin.

Pharmaceutical companies, such as Mirati Therapeutics, Inc., are developing Mocetinostat in combination with Brentuximab Vedotin in Phase I/II stage for Hodgkin’s lymphoma. Mocetinostat is an orally bioavailable and spectrum-selective Histone Deacetylase (HDAC) inhibitors. The drug candidate is believed to reverse aberrant acetylation resulting from histone acetyltransferase (HAT) mutations, thereby prohibiting tumor progression and reducing tumor burden in patients.

According to the National Cancer Institute, a part of the U.S. National Institutes of Health, an estimated 8,500 new cases and 1,120 deaths were reported in the U.S., in 2016, due to Hodgkin’s lymphoma.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/hodgkins-lymphoma-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of Hodgkin’s lymphoma therapeutics include Bristol-Myers Squibb Co., Merck & Co. Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Affimed Therapeutics AG, Aeterna Zentaris Inc., Incyte Corporation, and 4SC AG.

Multiple Myeloma Therapeutics Pipeline – Patent, Collaboration and Other Developments

Multiple Myeloma (MM) Therapeutics Pipeline

The multiple myeloma therapeutics pipeline is expected to witness considerable growth in the coming year due to high prevalence of the disease. The growth of multiple myeloma therapeutics pipeline is assisted by targeted therapy and new effective treatment. Also, increased awareness among the population about the various cancer treatments has further fueled the growth of the therapeutics pipeline. Increasing healthcare expenditure and technological advancements are supporting the growth of the therapeutics pipeline for multiple myeloma. An increasing demand for safe and effective medications is also driving the growth of the multiple myeloma therapeutics pipeline. Many government initiatives such as increased funding, designations and grants for speeding up the drug development process has also supported the growth of the therapeutics pipeline.

Explore Report at: https://www.psmarketresearch.com/market-analysis/multiple-myeloma-therapeutics-pipeline-analysis

The National Cancer Institute, which is a part of the U.S. National Institutes of Health, defines multiple myeloma as a cancer that is formed by malignant plasma cells. Normal plasma cells are found in the bone marrow as an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other diseases. Lymphocytes (lymph cells) are the main cell types of the human immune system and the major types of lymphocytes are T cells and B cells. When B cells respond to an infection, they mature and change into plasma cells. Plasma cells make the antibodies (also known as immunoglobulins) that help the body attack and kill germs. Lymphocytes are present in many areas of the body, such as lymph nodes, bone marrow, intestines, and the bloodstream. Plasma cells, however, are mainly found in the bone marrow. Bone marrow is the soft tissue found inside some hollow bones. In addition to plasma cells, the bone marrow has those cells that make the different normal blood cells.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/multiple-myeloma-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of myeloma therapeutics include Celgene Corporation, Bristol-Myers Squibb, Abbvie, Inc., Novartis AG, F. Hoffman La Roche AG, Amgen, Inc., Karyopharm Therapeutics, Inc., Array BioPharma, and Takeda Pharmaceutical Company Limited.

Thyroid Cancer Therapeutics Pipeline – Clinical Trials & Results, Patent and Developments

Thyroid Cancer Therapeutics Pipeline

The thyroid cancer therapeutics pipeline is expected to witness considerable growth due to increase in the demand for the targeted drug formulation for the treatment of cancer. Though less number of drugs are available for thyroid cancer treatment, an increasing awareness regarding cancer treatment and high demand for safe and effective medications are driving the therapeutics pipeline.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/thyroid-cancer-therapeutics-pipeline-analysis/toc-sample

According to the National Cancer Institute, a part of the U.S. National Institutes of Health, thyroid cancer is a rare type of cancer that affects the thyroid gland, a small gland at the base of the neck that produces hormones. It most commonly occurs in people aged 30-year-old. Women are two to three times more likely to develop this thyroid cancer, as compared to men. Thyroid cancer is usually treatable, and in many cases, can be cured completely, although it can sometimes come back after treatment. There are four main types of thyroid cancer; papillary thyroid cancer, follicular thyroid cancer (hurthle cell thyroid cancer), medullary thyroid cancer and anaplastic thyroid cancer.

Among the presently available drugs, Lenvatinib, a small molecule drug candidate of Eisai Co Ltd., was approved by USFDA on 13 February 2015. It is an orally active multi-targeted kinase inhibitor, which inhibits vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptors and other tyrosine kinases.

Pre-Purchase Enquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=thyroid-cancer-therapeutics-pipeline-analysis

Many pharmaceutical companies are focusing on the research and development of thyroid cancer therapeutics pipeline drug candidates, collaborating with one another. In February 2015, Biologics, Inc., an integrated oncology services company, reported that it was selected by Eisai Co. Ltd. as a specialty pharmacy provider within Eisai’s limited distribution network for Lenvima (lenvatinib).

Some of the key players having a pipeline of thyroid cancer therapeutics include Eisai & Co. Ltd., Exelixis, Amgen, AstraZeneca plc, Merck & Co., Inc., Daiichi Sankyo Company Limited, and F. Hoffmann-La Roche AG.

Amyotrophic Lateral Sclerosis Pipeline – Designation, Collaboration, and Other Developments

Amyotrophic Lateral SclerosisThe study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 72 drug candidates in different stages of development.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis

Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the degeneration leads to hardening and scarring of muscles in that region. The progressive degeneration of neurons from brain to the spinal cord and spinal cord to the whole body can ultimately lead to their death. Amyotrophic lateral sclerosis is classified into two types, namely, sporadic and familial. Approximately 90% to 95% of the patients suffering from the disease in the U.S. are experience the sporadic.

According to the route of administration analysis, most of the drug candidates are being developed to be administered by oral route.

Pre Purchase Enquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=amyotrophic-lateral-sclerosis-pipeline-analysis

NurOwn is a cell therapy platform that builds on the enormous research effort that has gone into developing mesenchymal stem cells (MSCs) as a treatment for human diseases.

Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, and others.

Acute Respiratory Distress Syndrome Therapeutics Pipeline – Designation, Collaboration, and Other Developments

The acute respiratory distress syndrome therapeutics pipeline is expected to witness nominal growth in the coming year due to the slow research and development activities of the pipeline drugs. Some of the factors driving the growth of the pipeline include approval of new therapies that include but are not limited to, tissue factor antagonists, cluster of differentiation modulators, p38 kinase inhibitors and DNA polymerase inhibitors. Also, increasing awareness regarding the acute respiratory distress syndrome treatment, high demand for safe and effective medications and technological advancements are also supporting the growth of the acute respiratory distress syndrome therapeutics pipeline.

Explore Report at: https://www.psmarketresearch.com/market-analysis/acute-respiratory-distress-syndrome-therapeutics-pipeline-analysis

According to American Lung Association, acute respiratory distress syndrome is a rapidly progressive disease occurring in critically ill patients. The main complication in acute respiratory distress syndrome is the leakage of fluid into the lungs that leads to difficulty in breathing. Acute respiratory distress syndrome, is a buildup of fluid in the tiny air sacs in the lungs called alveoli, resulting in less oxygen to the organs, which is very dangerous. Acute respiratory distress syndrome occurs when there is significant trauma that either affects the lungs directly or indirectly. Some of the traumas associated with the disease are sepsis (a blood infection), severe pneumonia, major trauma and shock from any cause. The body responds to this trauma with an inflammatory reaction that releases numerous natural molecules into the bloodstream. Normally, this inflammatory reaction would be protective and helps in fighting infections or healing of injuries. However, in some people, these inflammatory molecules are responsible for the leakage of fluid from the small blood vessels into lungs. Fluid leaves these small vessels and goes into the alveoli. The alveoli filled with this fluid, makes obstruction difficult for oxygen to get into the bloodstream.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/acute-respiratory-distress-syndrome-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of acute respiratory distress syndrome therapeutics include GlaxoSmithKline plc, Altor BioScience Corporation, Pfizer, Inc., BioLineRx, AbbVie, Inc., Amgen, Alliance Pharmaceutical Corporation, Daiichi Sankyo Co., Ltd. and Faron Pharmaceuticals Ltd.